Literature DB >> 12210859

Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.

François Tison1, Farid Yekhlef, Virginie Chrysostome, Eric Balestre, Niall P Quinn, Werner Poewe, Gregor K Wenning.   

Abstract

We analyzed parkinsonian features in multiple system atrophy (MSA) compared with age- and disease duration-matched Parkinson's disease (PD) patients, and assessed the applicability of the Unified Parkinson's Disease Rating Scale (UPDRS) -III motor scale as a means of rating their severity. Cross-sectional analysis of parkinsonism was done using UPDRS-III, International Cerebellar Atatia Rating Scale, and disability scales (Hoehn and Yahr [H&A], Schwab and England, Katz and Lawton) in 50 unselected MSA patients and in 50 matched PD patients. At symptom onset, falls occurred 10 times more frequently in MSA, whereas limb tremor was 10 times more common in PD. At first visit (10.2 months), hemiparkinsonism and pill-rolling rest tremor were less common in MSA. Hypomimia, atypical rest, postural or action tremor, as well as postural instability were more frequent in MSA. At study examination (62.4 months), parkinsonian signs in MSA patients were more frequently symmetrical and associated with axial rigidity, antecollis and postural instability. A levodopa response of >50% was seen in <10% of MSA patients. Modified H&Y stages (3.2 +/- 1.3 vs. 2.2 +/- 0.78) and UPDRS-III scores (48.14 +/- 19.5 vs. 31.74 +/- 12.9) were significantly (P = 0.0001) higher in MSA. The internal consistency of the UPDRS-III was fair in MSA patients (Cronbach's alpha >0.90), and correlated well with marked dependency on the Schwab and England and Katz and Lawton scales. Factor structure analysis of UPDRS-III in MSA showed five clinically distinct subscores accounting for 74% of the variance, differing from PD by the dependency of the face-speech and limb bradykinesia items and independence of the postural-action tremor from the rest tremor items. There was a significant correlation (R(2) = 0.70, P = 0.001) between ICARS ataxia and UPDRS-III scores in MSA patients. Results confirm a distinct profile of parkinsonism in MSA and greater severity and disability compared with PD. It also indicates that the UPDRS-III provides a useful severity measure of parkinsonism in MSA, albeit contaminated by additional cerebellar dysfunction. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210859     DOI: 10.1002/mds.10171

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Considerations before initiating therapy in Parkinsonism: basing on the quality of life.

Authors:  Shu-Jin He; Zhen-Yang Liu; Yu-Jie Yang; Cong Shen; Yu-Jie Du; Xin-Yue Zhou; Jue Zhao; Yi-Min Sun; Ke Yang; Jian-Jun Wu; Feng-Tao Liu; Jian Wang
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

Review 2.  The European Multiple System Atrophy-Study Group (EMSA-SG).

Authors:  F Geser; K Seppi; M Stampfer-Kountchev; M Köllensperger; A Diem; J P Ndayisaba; K Ostergaard; E Dupont; A Cardozo; E Tolosa; M Abele; R Dodel; T Klockgether; I Ghorayeb; F Yekhlef; F Tison; C Daniels; F Kopper; G Deuschl; M Coelho; J Ferreira; M M Rosa; C Sampaio; M Bozi; A Schrag; J Hooker; H Kim; T Scaravilli; C J Mathias; C Fowler; N Wood; N Quinn; H Widner; C F Nilsson; O Lindvall; N Schimke; K M Eggert; W Oertel; F del Sorbo; F Carella; A Albanese; M T Pellecchia; P Barone; R Djaldetti; G Meco; C Colosimo; A Gonzalez-Mandly; J Berciano; T Gurevich; N Giladi; M Galitzky; F Ory; O Rascol; C Kamm; K Buerk; S Maass; T Gasser; W Poewe; G K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

3.  [A biomechanical analysis of cyclical hand motor function: a pilot study in different Parkinsonian syndromes].

Authors:  T Wolfsegger; I Rotaru; R Topakian; R Pichler; M Sonnberger; F T Aichner; H Schwameder
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

4.  Progression of parkinsonism in multiple system atrophy.

Authors:  Klaus Seppi; Farid Yekhlef; Anja Diem; Elisabeth Luginger Wolf; Joerg Mueller; François Tison; Niall P Quinn; Werner Poewe; Gregor K Wenning
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

5.  Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.

Authors:  Randel L Swanson; Andrew B Newberg; Paul D Acton; Andrew Siderowf; Nancy Wintering; Abass Alavi; P David Mozley; Karl Plossl; Michelle Udeshi; Howard Hurtig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

6.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

7.  Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study.

Authors:  Christian Brenneis; Karl Egger; Christoph Scherfler; Klaus Seppi; Michael Schocke; Werner Poewe; Gregor K Wenning
Journal:  J Neurol       Date:  2007-02       Impact factor: 4.849

Review 8.  Diagnosis of multiple system atrophy.

Authors:  Jose-Alberto Palma; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  Auton Neurosci       Date:  2017-10-23       Impact factor: 3.145

9.  Resistance training with instability in multiple system atrophy: a case report.

Authors:  Carla Silva-Batista; Hélcio Kanegusuku; Hamilton Roschel; Eduardo O Souza; Telma F Cunha; Gilberto C Laurentino; N Manoel; Marco T De Mello; Maria E P Piemonte; Patrícia C Brum; Claudia L Forjaz; Valmor Tricoli; Carlos Ugrinowitsch
Journal:  J Sports Sci Med       Date:  2014-09-01       Impact factor: 2.988

Review 10.  Evolving concepts on bradykinesia.

Authors:  Matteo Bologna; Giulia Paparella; Alfonso Fasano; Mark Hallett; Alfredo Berardelli
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.